Gordon Jayson
University of Manchester · The Christie NHS Foundation Trust · The Christie National Health Service (NHS) Foundation Trust
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gordon Jayson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:05 UTC. Open this list on ClinicalTrials.gov
- N/ANCT04523116 · Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors: VALTIVE1University of Manchester · unknown · Ovary Cancer · principal investigator
- Ph2NCT03570437 · Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?University of Manchester · unknown · Carcinosarcoma, Endometrial Neoplasms · principal investigator
- Early Ph1NCT02855697 · Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian CancerThe Christie NHS Foundation Trust · completed · Ovarian Cancer · study chair
- Ph1/Ph2NCT02055690 · PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian CancerThe Christie NHS Foundation Trust · terminated · Ovarian Neoplasms, Neoplasms, Ovarian, Ovarian Cancer · study chair
- Ph1NCT01147029 · GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to TherapyCancer Research UK · terminated · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph1NCT00005061 · Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid TumorsEuropean Organisation for Research and Treatment of Cancer - EORTC · completed · Unspecified Adult Solid Tumor, Protocol Specific · study chair
- Ph2NCT00004008 · Bryostatin 1 in Treating Patients With Ovarian Epithelial CancerUniversity of Glasgow · completed · Ovarian Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:05 UTC. The ranking covers the 200 most relevant of 49 PubMed records, and a shared surname and initials can bring in a namesake. All 49 on PubMed
- 1,077 citationsRCR 37.5
- 907 citationsRCR 19.6
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.Lancet Oncol · 2015683 citationsRCR 21.5
- Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.J Natl Cancer Inst · 2004471 citationsRCR 10.5
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.Lancet · 2010412 citationsRCR 10.1
- Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.J Natl Cancer Inst · 2002213 citationsRCR 4.8
- 180 citationsRCR 5.6
- Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.J Clin Oncol · 2011172 citationsRCR 4.1
- Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.Ann Oncol · 2011141 citationsRCR 4.0
- 125 citationsRCR 2.5